IMA

NASDAQ 已收盘

ImageneBio

3.92 USD
▼-0.06-1.51%
盘后 3.41 0.00%
2026-11-20
市值
$44.50M
市盈率
—
EPS
-3.29
股息率
—
52 周区间
3.00 – 7.69
成交量
44.33K
Beta
—
目标价
18.00
52W 低 3.0052W 高 7.69
价格走势

公司简介

ImageneBio, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for patients with immunological, autoimmune and inflammatory diseases. Its lead product candidate includes IMG-007, a non-depleting anti-OX40 monoclonal antibody that binds to OX40 receptor on activated T cells to block receptor binding to OX40 ligand which is in Phase 1b/2a clinical trial. The company was formerly known as Ikena Oncology, Inc. and changed its name to ImageneBio, Inc. in July 2025. ImageneBio, Inc. is headquartered in San Diego, California.